7th Annual Oligonucleotides for CNS Summit

The 7th Annual Oligonucleotides for CNS Summit advances central nervous system oligonucleotide therapeutics by exploring precision delivery technologies, antisense and RNAi strategies, brain-targeted platforms, and translational approaches for neurological and neurodegenerative diseases.

Key Topics

• Brain-targeted oligonucleotide delivery systems
• Non-invasive blood-brain barrier transport technologies
• Antisense oligonucleotide therapeutics for neurodegenerative diseases
• Ai-driven microRNA target discovery and patient stratification
• Gene silencing and splice-switching strategies in the cns
• Parkinson’s disease oligo therapeutic development
• Precision receptor diversification and brain-centric shuttles
• Programmable cell-selective rnai platforms
• Intrathecal sirna distribution and uptake optimization
• Novel biologics platforms for cns targeting
• Aptamer-based cns therapeutics and delivery systems
• Nanotherapeutics, peptide carriers, and aav delivery approaches
• Predictive cns toxicity modeling and safety assessment
• Splice correction strategies for als and tdp-43 diseases
• Gene upregulation therapies for syngap1 disorders
• Oligonucleotide chemistry, conjugation, and duplex design
• Manufacturing scalability and commercial development challenges
• Neurological disease target validation using human genetics
• Mrna-based drug development and therapeutic innovation
• Regulatory alignment and clinical translation of cns oligos

Who should Attend

• Neuroscience and neurobiology researchers
• Professionals in oligonucleotide and rna therapeutics
• Biotechnology and pharmaceutical scientists
• Clinical researchers in neurological disorders
• Drug delivery and biomaterials specialists
• Experts in antisense, sirna, and microrna technologies
• Translational medicine and clinical development teams
• Regulatory and safety professionals in therapeutics
• Ai and computational biology researchers
• Industry leaders in cns drug discovery and development